- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Rossari Biotech collects Rs 149 crore from anchor investors ahead of IPO
Rossari Biotech's initial share-sale will end four months of inactivity in the IPO markets. SBI Cards & Payment Services was the last company to float IPO in March.
New Delhi: Specialty chemicals manufacturer Rossari Biotech on Friday said it has raised Rs 149 crore from anchor investors ahead of its initial share-sale that opens on Monday.
The anchor investors include Abu Dhabi Investment Authority, HDFC Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, SBI Mutual Fund, Sundaram Mutual Fund, HDFC Life Insurance Company, and Goldman Sachs India.
In a statement, the company said it has raised Rs 148.87 crore in anchor allotment and has finalized allocation of 35,02,940 shares to 15 institutional investors at Rs 425 per share, which is the upper limit of the price band for the IPO.
The company has fixed a price band of Rs 423-425 per equity share for its initial public offer (IPO) which will be open for public subscription from July 13-15.
Rossari Biotech's initial share-sale will end four months of inactivity in the IPO markets. SBI Cards & Payment Services was the last company to float IPO in March.
Rossari Biotech's IPO comprises fresh issuance of shares worth Rs 50 crore and the sale of 1,05,00,000 equity shares by the company's promoters through offer-for-sale route.
At the upper end of the price band, the IPO size is about Rs 496 crore.
The company has already raised Rs 100 crore in pre-IPO placement.
Net proceeds from the issue will be utilized for funding working capital requirements, repaying certain debt availed by the company, and for general corporate purposes.
Axis Capital and ICICI Securities are the merchant bankers for the share-sale. The equity shares will be listed on the NSE and BSE.
The company, which filed its draft papers with Sebi in December 2019, received clearance from the regulator in February to launch the IPO.
Rossari Biotech is a specialty chemical manufacturing firm with a focus on home and personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition products.
Apart from India, it has operations in 17 countries, including Vietnam, Bangladesh, and Mauritius.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751